Peter Rossing
Researcher Next ID · RN-021296
Researcher · Medicine
Copenhagen, Denmark
- Works count
- 1,393
- Citation count
- 82,058
- H-index
- 123
- i10-index
- 630
Research interests
Publications
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2410659
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
The Lancet Diabetes & Endocrinology · 2024 · https://doi.org/10.1016/s2213-8587(24)00271-7
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2403347
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Nephrology Dialysis Transplantation · 2023 · https://doi.org/10.1093/ndt/gfad009
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
European Heart Journal · 2023 · https://doi.org/10.1093/eurheartj/ehad192
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Diabetes Care · 2022 · https://doi.org/10.2337/dc22-0294
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Diabetes Care · 2022 · https://doi.org/10.2337/dci22-0027
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Kidney International · 2022 · https://doi.org/10.1016/j.kint.2022.06.008
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetologia · 2022 · 10.1007/s00125-022-05787-2
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetes Care · 2022 · https://doi.org/10.2337/dci22-0034
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Circulation · 2021 · https://doi.org/10.1161/circulationaha.121.055459
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
European Heart Journal · 2021 · 10.1093/eurheartj/ehab777
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2025845
Dapagliflozin in Patients with Chronic Kidney Disease
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2024816
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
European Heart Journal · 2019 · https://doi.org/10.1093/eurheartj/ehz486
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetes Care · 2019 · 10.2337/dci19-0066
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Nephrology Dialysis Transplantation · 2019 · https://doi.org/10.1093/ndt/gfz290
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Nephrology Dialysis Transplantation · 2019 · https://doi.org/10.1093/ndt/gfz290
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetologia · 2019 · https://doi.org/10.1007/s00125-019-05039-w
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetologia · 2018 · 10.1007/s00125-018-4729-5
A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes
Diabetes · 2018 · https://doi.org/10.2337/db17-0914
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetes Care · 2018 · https://doi.org/10.2337/dci18-0033
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
The Lancet Diabetes & Endocrinology · 2017 · https://doi.org/10.1016/s2213-8587(17)30194-8
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
BMC Nephrology · 2016 · https://doi.org/10.1186/s12882-016-0337-0
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
JAMA · 2015 · 10.1001/jama.2015.10081
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
The Lancet · 2012 · 10.1016/s0140-6736(12)61350-6
Current projects
No projects listed.